

Data Sharing Statement

Jackson DJ, Wechsler ME, Jackson DJ, et al. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. N Engl J Med. DOI: 10.1056/NEJMoa2406673.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	—
Which data?	Complete de-identified patient data set
Additional information about data	—
How or where can the data be obtained?	Anonymized individual participant data and study documents can be requested for further research at https://www.gsk-studyregister.com/en/
When will data availability begin?	Within 6 months post US and EU regulatory approval and publication of this study
When will data availability end?	—
Will any supporting documents be available?	—
Which supporting documents?	—
Additional information about supporting documents	—
How or where can supporting documents be obtained?	Supporting documents can be requested at https://www.gsk-studyregister.com/en/
When will supporting documents availability begin?	—
When will supporting documents availability end?	—
To whom will data be available?	Researchers whose proposed use of the data has been approved
For what type of analysis or purpose?	For research purposes, upon approval of request
By what mechanism?	After approval of a proposal, anonymized data is shared through a controlled, secure environment
Any other restrictions?	—
Additional information	—

This statement was posted on September 9, 2024, at NEJM.org.